Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page

Carotid stenting in asymptomatic patients: To do or not to do?

Thursday, 08 Mar 2012 16:40
David Sacks
David Sacks

By David Sacks

With regard to carotid stenting of asymptomatic patients, how is it that so many people can analyse the same data and draw such differing conclusions? In the United States, Medicare convened a panel of experts from professional societies to discuss whether carotid stenting is an appropriate treatment for asymptomatic carotid stenosis. Opinions ranged from definitely and unequivocally “yes” to equally emphatic “no”.


While carotid endarterectomy has been proved effective in preventing stroke in asymptomatic patients, the trials are ancient in terms of best medical therapy. Best medical therapy, with optimal (rather than routine) control of lipids, blood pressure, diabetes, and smoking, continues to improve but it is unlikely to reduce the stroke risk of an asymptomatic stenosis to zero. Therefore there should be a benefit to revascularisation, if performed with minimal morbidity and reasonable expense.


Comparing carotid stenting vs. carotid endarterectomy, CREST (Carotid revascularization endarterectomy vs. stenting trial) reported that the 30-day stroke/death rate for asymptomatic patients was 2.5% for carotid stenting vs. 1.4% for carotid endarterectomy. If post procedure myocardial infarction was included, carotid stenting and carotid endarterectomy had comparable outcomes, but it is unclear if myocardial infarction is a relevant outcome. It is a marker for long-term mortality, but it is possible that an asymptomatic “chemical” myocardial infarction does not necessarily cause increased mortality but instead simply indicates significant underlying coronary disease that itself causes late mortality. For symptomatic patients, the ICSS (International carotid stenting study) similarly showed roughly double the risk of stroke/death from carotid stenting as compared to carotid endarterectomy, as have analyses from national databases and from the Society for Vascular Surgery (SVS) carotid revascularisation registry. Furthermore, carotid stenting is significantly more expensive than carotid endarterectomy.


These data suggest that carotid stenting should not be performed if carotid endarterectomy is an option, and perhaps not performed at all if carotid stenting cannot meet the improved outcomes from best medical therapy. However, CREST also showed that stroke/death was far less common in the second half of the study, suggesting that truly contemporary carotid stenting outcomes easily match carotid endarterectomy and beat best medical therapy. In addition, cranial nerve injuries occur in about 5% of carotid endarterectomy patients. From a patient’s perspective it does not matter if a neurologic deficit was caused by a central or peripheral nerve injury. Most cranial nerve injuries are minor and resolve with time, but so do most minor strokes. If cranial nerve injuries were included in the 30-day stroke/death statistics carotid stenting and carotid endarterectomy would be comparable, although carotid stenting still has a higher mortality rate.

The results of CREST may not be generalisable. CREST recruited highly experienced operators with proven good outcomes and rejected half of the physicians who applied. Despite this selection, it was only after six years and half the patients had been enrolled that morbidity dropped. In ICSS, the physician could be performing his first case, albeit with a proctor, and could operate independently after 10 cases. ICSS is likely more representative of general practice and demonstrated carotid stenting outcomes for symptomatic patients that did not meet acceptable benchmarks. The learning curve reported in CREST was confirmed in ICSS and other studies. ICSS reported that centres treating <50 patients had 30-day stroke/death/myocardial infarction rate of 10% vs 5.9% for centres treating >50 patients. CAPTURE 2 (Carotid Acculink/Accunet post approval trial to uncover rare events) reported a facility threshold of 72 cases to consistently achieve a stroke/death rate rate <3%. An analysis of Medicare data from nearly 25,000 procedures reported the mean annual operator volume was only three carotid stenting cases/year. Low volume operators (<six carotid stenting cases/year) had nearly double the mortality (2.5% vs. 1.4%) of high volume operators (>24 carotid stenting /year).

The concern about lack of generalisability of good outcomes is being addressed in the US through independent accreditation of carotid stent facilities which requires meeting the American Heart Association thresholds of 30-day stroke/death rate of 3%/6% for asymptomatic/symptomatic patients. Outcomes-based accreditation is available through the ICACSF (www.icacsf.org) or ACE (bit.ly/wzj6US) but at the time of writing is not required by Medicare.


Should asymptomatic patients be treated with carotid stenting? It depends on how good the carotid stenting and endarterectomy operators are outside of trials, but more importantly, it depends on the outcomes from truly best medical therapy. These outcomes determine whether or not the procedure is suitable for reimbursement. The final answer to this question will probably end up depending on the proposed CREST 2 trial comparing best medical therapy to carotid stenting and carotid endarterectomy.


David Sacks is past president of the Society of Interventional Radiology (SIR) and president of the Intersocietal Commission for the Accreditation of Carotid Stent Facilities (ICACSF)

Add New Comment

Related Items

Most popular

“I felt indestructible”: The invisible impact of radiation
Thursday, 24 Sep 2015
A video featuring renowned American cardiovascular surgeon Edward Diethrich draws attention to the dangers of working with radiation, as it follows his journey in which he discovers that he has a ... “I felt indestructible”: The invisible impact of radiation

“We all need the strength” to challenge unacceptable behaviour
Thursday, 20 Aug 2015
The editors of Annals of Internal Medicine have called for doctors to confront colleagues who act in a disrespectful manner towards patients after an anonymous essay in the journal highlighted ... “We all need the strength” to challenge unacceptable behaviour

IR insertion of chest ports costs nearly half as much as those by surgery
Thursday, 10 Sep 2015
Research published in the Journal of the American College of Radiology in June suggests that hospital costs to place a chest port were significantly lower in the interventional radiology suite than ... IR insertion of chest ports costs nearly half as much as those by surgery


In clinical practice, prostate artery embolization “still in its infancy”
Thursday, 24 Sep 2015
Maurizio Grosso, tells Interventional News about the preliminary data being collected in the Italian prostate artery embolization registry and the encouraging results being obtained with the new ... In clinical practice, prostate artery embolization “still in its infancy”

How to avoid complications with prostate artery embolization
Thursday, 24 Sep 2015
In order to avoid major complications with prostate artery embolization, it is vital to look for collaterals to arteries of the surrounding organs to the prostate, writes João Pisco. How to avoid complications with prostate artery embolization


Lindsay Machan
Thursday, 28 May 2015
“Focusing on maximising rewards has sidelined more ideas than it has helped individual inventors. S... Lindsay Machan

Gao-Jun Teng
Thursday, 11 Dec 2014
In the future, will interventional radiology be a subspecialty of radiology, or surgery? asks Gao-J... Gao-Jun Teng

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions